ACP-105
Muscle Building · SARM
Tier D+
What this is
Obscure SARM with minimal human exposure. Acadia stopped development years ago. Sold by research chemical vendors with standard SARM pitch despite absence of efficacy or safety data in humans.
Mechanism
Non-steroidal partial AR agonist; developed by Acadia Pharmaceuticals originally for cognitive indications in hypogonadism; tissue-selective profile claimed
Dose & route
Typical illicit: 5-15 mg/day PO
Citations
- https://pubmed.ncbi.nlm.nih.gov/17444687/
- https://patents.google.com/patent/US7214690B2/en
- https://pubmed.ncbi.nlm.nih.gov/29378245/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.